Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target

Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data

Video

Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.

________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.

His research activities include atherosclerosis, lipid apheresis, vascular inflamation and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.

Related Content

Investigational Oral Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data / image credit Stephen Nicholls, MBBS, PhD Monash University

Mary Caffrey

November 19th 2024

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.

August 30th 2023

Aprocitentan Now Available in the US for Treatment-Resistant Hypertension

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

November 15th 2024

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

Patient Care Editorial Staff

October 29th 2020

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

November 11th 2024

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

November 5th 2024

Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Related Content

Mary Caffrey

November 19th 2024

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.

August 30th 2023

Aprocitentan Now Available in the US for Treatment-Resistant Hypertension

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

November 15th 2024

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.

Patient Care Editorial Staff

October 29th 2020

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

November 11th 2024

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

November 5th 2024